Targeted sequencing Vs Comprehensive RNA-Seq

From GenomeWeb – By Monica Heger

Targeted sequencing of select gene panels may miss druggable mutations in cancer patients when compared to a more comprehensive sequencing strategy that includes RNA-seq, according to several case studies presented at last weekend’s Personal Genomes meeting at Cold Spring Harbor Laboratory.

Both Elaine Mardis, co-director of the Genome Institute at Washington University, and Karin Kassahn, a researcher in Sean Grimmond’s lab at the University of Queensland in Brisbane, presented case studies of patients for whom druggable mutations were identified via a comprehensive sequencing strategy.

(